About Us » Management Team
About Us

Management Team

  • Dr. Patrick Liu

    Chairman and Acting CEO of
    GenScript Probio

    • Bachelor of Science in biochemistry and molecular biology from Nankai University in the PRC, Master’s degree in neurophysiology from Peking University in the PRC, and Doctor of Philosophy in neurobiology from University of Pittsburgh School of Medicine in the U.S.
    • Possesses over 14 years of R&D and management experience in the life-science and biologics development industry.
    • Appointed as the General Manager of the Reagent Service Business Unit of GenScript Biotech from September 2015 to April 2019, leading the rapid development and establishing GenScript's leading position in global market.
    • Served as the President of the Biosciences Group of GenScript Biotech from January 2017 to April 2019, responsible for formulating future strategic planning and development.
    • Appointed as the rotating Chief Executive Officer of GenScript Biotech in August 2020, responsible for strategic planning and execution, internal resource optimization and integration, and operational management.
    • As a core team member, led the formation of GenScript Probio, actively participating in and facilitating multiple rounds of financing for the company.
    • Appointed as Chairman of the Board of Directors of GenScript Probio in August 2022
    • Appointed as Acting CEO of GenScript Probio in June 2023.

  • Daniel Wang

    Chief Operating Officer (COO)

    • Rich experience in CRO and CDMO business operations, leading a team of more than 1,000 people
    • 10+ years' experience in team management, rich experience in multi-functional management such as production, R&D, business development and integrated operations
    • 14+ years' experience in protein expression and biologics development
    • Led the establishment of GenScript biologics CDMO platform and team; Led the establishment of GenScript biologics CDMO business unit.

  • Dr. Nathan Mao

    Chief Technology Officer (CTO)

    • 20+ years of experience in biologic drugs and vaccines development and cGMP manufacturing
    • Increasing management responsibilities at Biogen, Pfizer and Regeneron
    • Experience in both clinical & commercial manufacturing and support including ten commercially marketed medicines and blockbusters in U.S., EU and ROW
    • Leadership experience in building new modality programs such as Cell & Gene Therapy, viral and non-viral delivery systems, mRNA, siRNA, VLP, ADC, CRISPR/Cas9, LNP
    • Ph.D. from Brown University

  • Ben Chen

    Chief Quality Officer (CQO)

    • M.S. degree in Biotechnology Enterprise from Johns Hopkins University, Bachelor of Science in Chemical Engineering from Purdue University
    • Obtained a Professional Engineering license in the U.S., certified as a Six Sigma Green Belt and lean manufacturing
    • 28+ extensive biopharmaceutical experience in leading quality, manufacturing, and engineering professionals in the U.S., Europe, and Asia
    • Various positions of increasing responsibility at Genentech, Bristol-Myers Squibb, Novartis, Eli Lilly, Baxter, Impax and Wuxi Biologics before joining the company

  • Fredy Chu

    VP of US GMP Quality

    • M.S., Analytical Chemistry, Iowa State University
    • 30+ years in pharma/biologics quality management
    • Baxter, Collagen, ChemPartner, PharmaEssentia, Kanghong, Xoma, Fibrogen
    • Responsible for FDA, EMA PAI approvals in US and Asia
    • Multiple successful GMP facility validation in US and Asia
    • Experienced in QA/QC management of multi-site global pharma/biotech
    • Seasoned quality practitioner in drug development, clinical and commercial operations in US, Asia, and EU

  • Dr. Sean Liour

    VP of PM&RA

    • Ph.D. from Virginia Commonwealth University
    • 10+ years' experience in biologics project management
    • Fountain Biopharma, development of a novel therapeutic antibody project, IND filing and phase I study
    • 2016 joined Shanghai Henlius Biotech, participated in the development and IND/NDA filing of novel antibody drug-conjugate (ADC), novel antibodies and biosimilars.

  • Dr. Yu Liang

    VP of ADD Business Center

    • Ph.D. in Virology/Microbiology from the University of Chicago
    • Research Fellow, NIAID, NIH
    • PI/lab head, Novartis Inst. for Biomedical Research (Shanghai)
    • WuXi Biologics Discovery, Senior Project Leader and Portfolio Director
    • Over 20 years of research experience in biomedical science in academia and industry, with 10+ years of managerial experience in leading a global & multi-disciplinary project team in leading multinational pharmaceutical companies
    • Broad and in-depth knowledge & experience in early phase drug discovery of bio-therapeutics, with special expertise in the discovery of therapeutic modalities based on therapeutic Abs